Research
Cellular
Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.
Clinicians should monitor for gastrointestinal side effects when prescribing maridebart cafraglutide.
StrongQualifiesmedium confidence
Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.
Why this rating
Based on the phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2504214
rct · n=592Cited 55×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.Strong
- In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →